Ourself.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No.: 30523/125/ANRC

In re patent application of William H. Velander, et al.

35erial No. 08/443,184

May 17, 1995

Group Art Unit:

1804

Examiner:

Unknown

For:

iled:

TRANSGENIC FIBRINOGEN

RECEIVED

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 and 1.97(e)(1)

SEP 3 0 1995

CROUP THAT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. § 1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

Serial No. 08/443,184

CONCISE EXPLANATION OF RELEVANCE OF EACH DOCUMENT

Applicants are submitting herewith on Form PTO-1449, a listing of the documents cited by or submitted to the Patent Office in parent application Serial No. 08/198,068, filed February 18, 1994. The relevance of these prior art documents is explained in the parent application.

As provided in 37 C.F.R. §1.98(d), copies of the above documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. 08/198,068 filed February 18, 1994.

Documents A22 through A29 came to applicants' attention during the prosecution of the corresponding European application. A copy of the Search Report is attached setting forth the portion of each document considered relevant by the examiner. English-language counterparts of foreign-language documents have been provided where available.

Copies of documents A22 through A29 are being submitted to comply with the provisions of 37 CFR 1.97-1.99.

Since this Information Disclosure Statement is being filed in compliance with 37 C.F.R. §1.97(b) within three (3) months of the filing date, or before the first action on the merits, no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialled copy of Form PTO-1449 be returned in accordance with M.P.E.P. § 609.

Respectfully submitted,

Date

Melvin Blecher, Ph.D. Registration No. 33,649

FOLEY & LARDNER
3000 K Street, N.W.
Suite 500
Washington, D.C. 2007-5109

Tel: (202) 672-5300